Your Source for Venture Capital and Private Equity Financings

Venture Capital News: MBX Biosciences Closes $115M Series B

2022-11-14
CARMEL, IN, MBX Biosciences, a clinical stage biopharmaceutical company, announced the closing of a $115 million Series B financing.
MBX Biosciences, Inc., a clinical stage biopharmaceutical company developing Precision Endocrine Peptide (PEP) therapeutics to treat an array of endocrine disorders, announced the closing of a $115 million Series B financing. The Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors